Global trends and predictions in ovarian cancer mortality

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2017-2025

  Malvezzi, M ^a,b   Carioli, G ^b   Rodriguez, T ^c   Negri, Eva ^a   La Vecchia, C ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Universidad Pública de Navarra   (Spain)

Author keywords

Diet; Menopausal hormone replacement therapy; Mortality; Oral contraceptives; Ovarian cancer; Treatment

Indexed keywords

ADULT; AGE; AGED; ARGENTINA; ARTICLE; AUSTRALIA; CANCER INCIDENCE; CANCER MORTALITY; CHILE; EUROPEAN UNION; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; ILLNESS TRAJECTORY; JAPAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PREVALENCE; PRIORITY JOURNAL; TREND STUDY; UNITED STATES; EUROPE; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TRENDS; WORLD HEALTH ORGANIZATION;

AUSTRALIA; EUROPE; FEMALE; HUMANS; JAPAN; MORTALITY; OVARIAN NEOPLASMS; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 84987599129     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw306     Document Type: Article

References (39)

1. Bosetti C, Bertuccio P, Malvezzi M et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann Oncol 2013; 24: 2657-2671
2. Lowe KA, Chia VM, Taylor A et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 2013; 130: 107-114
3. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29
4. Ryerson AB, Eheman CR, Altekruse SF et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016; 122: 1312-1337
5. Bray F, Loos AH, Tognazzo S et al. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2005; 113: 977-990
6. Cibula D, Gompel A, Mueck AO et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631-650
7. Collaborative Group on Epidemiological Studies of Ovarian CancerBeral V, Doll R et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23, 257 women with ovarian cancer and 87, 303 controls. Lancet 2008; 371: 303-314
8. McGuire V, Hartge P, Liao LM et al. Parity and oral contraceptive use in relation to ovarian cancer risk in older women. Cancer Epidemiol Biomarkers Prev 2016; 25: 1059-1063
9. La Vecchia C, Rota M, Malvezzi M et al. Potential for improvement in cancer management: reducing mortality in the European Union. Oncologist 2015; 20: 495-498
10. Malvezzi M, Carioli G, Bertuccio P et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol 2016; 27: 725-731
11. World Health Organization Statistical Information System. WHO Mortality Database. Geneva: World Health Organization; http://www.who.int/healthinfo/statistics/mortality_rawdata/en/index.html (3 November, 2014, date last accessed)
12. World Health Organization. International Classification of Disease: 8th Revision. Geneva: World Health Organization 1965
13. World Health Organization. International Classification of Disease: 9th Revision. Geneva: World Health Organization 1977
14. World Health Organization. International Classification of Disease and related Health Problems: 10th Revision. Geneva: World Health Organization 1992
15. Doll R, Smith PG, Waterhouse JAH et al. Comparison between registries: agestandardized rates. Cancer Incidence in Five Continents, Vol. IV. IARC Scientific Publications No. 42. Lyon: IARC. 1982; 671-675
16. Kim HJ, Fay MP, Feuer EJ et al. Permutation tests for joinpoint regression with applications to cancer rates. (Erratum in: Stat Med 2001;20: 655). Stat Med 2000; 19: 335-351
17. Clegg LX, Hankey BF, Tiwari R et al. Estimating average annual per cent change in trend analysis. Stat Med 2009; 28: 3670-3682
18. National Cancer Institute. Joinpoint Regression Program, version 4.1. 2014; http://srab.cancer.gov/joinpoint/
19. European Commission. Eurostat population database. 2014 (July, date last accessed)
20. Bureau UC. 2014 National Population Projections. 2014; http://www.census.gov/population/projections/data/national/2014.html (January 2016, date last accessed)
21. Research NIoPaSS. Japanese National Institute of Population and Social Security Research. http://www.ipss.go.jp/index-e.asp (May 2012, date last accessed)
22. Chatenoud L, Bertuccio P, Bosetti C et al. Trends in mortality from major cancers in the Americas: 1980-2010. Ann Oncol 2014; 25: 1843-1853
23. Mathers CD, Fat DM, Inoue M et al. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ 2005; 83: 171-177
24. Yang HP, Anderson WF, Rosenberg PS et al. Ovarian cancer incidence trends in relation to changing patterns of menopausal hormone therapy use in the United States. J Clin Oncol 2013; 31: 2146-2151
25. The ESHRE Capri Workshop Group, Crosignani PG, Glasier A. Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception. Hum Reprod Update 2012; 18: 670-681
26. Tarone RE, Chu KC. Age-period-cohort analyses of breast-, ovarian-, endometrialand cervical-cancer mortality rates for Caucasian women in the USA. J Epidemiol Biostat 2000; 5: 221-231
27. Collaborative Group on Epidemiological Studies of Ovarian CancerBeral V, Gaitskell K et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015; 385: 1835-1842
28. The ESHRE Capri Workshop Group. Continuation rates for oral contraceptives and hormone replacement therapy. Hum Reprod 2000; 15: 1865-1871
29. Lee AW, Ness RB, Roman LD et al. Association between menopausal estrogenonly therapy and ovarian carcinoma risk. Obstet Gynecol 2016; 127: 828-836
30. Negri E, Tzonou A, Beral V et al. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999; 80: 848-851
31. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
32. Bosetti C, Bertuccio P, Levi F et al. The decline in breast cancer mortality in Europe: an update (to 2009). Breast 2012; 21: 77-82
33. Fernandez E, La Vecchia C, Gonzalez JR et al. Converging patterns of colorectal cancer mortality in Europe. Eur J Cancer 2005; 41: 430-437
34. Parazzini F, Franceschi S, La Vecchia C et al. The epidemiology of ovarian cancer. Gynecol Oncol 1991; 43: 9-23
35. La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev2016 PMID 27457053
36. Luan NN, Wu QJ, Gong TT et al. Breastfeeding and ovarian cancer risk: a metaanalysis of epidemiologic studies. Am J Clin Nutr 2013; 98: 1020-1031
37. The ESHRE Capri Workshop Group. Europe the continent with the lowest fertility. Hum Reprod Update 2010; 16: 590-602
38. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25, 157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012; 9: e1001200
39. Edefonti V, Decarli A, La Vecchia C et al. Nutrient dietary patterns and the risk of breast and ovarian cancers. Int J Cancer 2008; 122: 609-613